Navana Pharma sponsor to transfer 16 lakh shares to managing director
The company attributed the 31.5% year-on-year growth in quarterly earnings to higher sales revenue and improved cost management.
Sponsor Manzurul Islam of Navana Pharmaceuticals PLC is set to transfer 16.04 lakh shares to the company's Managing Director, Md Jonaid Shafiq, through an off-market transaction approved by the Dhaka Stock Exchange (DSE).
According to a DSE disclosure, the shares will be transferred outside the trading system within the next 30 working days, effective from 2 August. The transfer will be executed through an off-market transaction and is not a gift.
Meanwhile, the listed drug maker continues to deliver strong financial results. In the January-March quarter of FY26, Navana Pharmaceuticals reported earnings per share (EPS) of Tk1.22, up from Tk1.01 in the same period a year earlier.
Keep updated, follow The Business Standard's Google news channel
For the first nine months of FY2025-26, EPS rose to Tk4.59 from Tk3.49 a year ago.
The company attributed the 31.5% year-on-year growth in quarterly earnings to higher sales revenue and improved cost management.
Net operating cash flow per share increased to Tk15.44 from Tk10.22 during the period, driven by higher cash collections from customers, while net asset value per share stood at Tk49.53 as of 31 March 2026.
Navana Pharmaceuticals is also advancing a €26.61 million foreign loan facility with a 12-year tenure from Germany-based AKA Ausfuhrkredit-Gesellschaft mbH, arranged by KGMC Financial Service, Bangladesh.
Subject to regulatory approvals and due diligence, the financing will be used to expand the company's production capacity.
